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We collected sputum samples and cough plates from 15 
cystic fibrosis patients in the Netherlands who were colo-
nized with Aspergillus fumigatus; we recovered A. fumiga-
tus of the same genotype in cough aerosols and sputum 
samples from 2 patients. The belief that transmission of 
A. fumigatus from cystic fibrosis patients does not occur 
should be reconsidered.
Progressive lung injury in cystic fibrosis (CF) patients can lead to chronic colonization with bacteria and fun-
gi (1,2). Different routes of patient-to-patient transmission 
have been identified for various microorganisms (3). For 
saprophytic molds, such as Aspergillus fumigatus, exposure 
to aerosolized conidia in the environment is believed to be 
the primary route leading to colonization of the airways (3). 
Secretion of these fungi from the human lung into the en-
vironment is thought not to occur, and the general view is 
that humans are dead-end hosts of filamentous fungi. How-
ever, some reports have provided information suggesting 
that this belief might need to be revised (4). We set out to 
examine whether aerosol formation of A. fumigatus occurs 
in CF patients during coughing.
The Study
During 2017–2018, we invited 15 adult CF patients in the 
Netherlands who were colonized with A. fumigatus to par-
ticipate in a cough plate experiment. We defined A. fumiga-
tus colonization as the recovery of A. fumigatus from >50% 
of sputum samples collected over the course of the 2 pre-
vious years. To enable genetic comparisons among study 
samples, we stored cultured fungal isolates from included 
patients in the Radboud University Medical Center Medi-
cal Microbiology Department (Nijmegen, the Netherlands) 
fungal species bank. We performed sample collection 
during 2 routine quarterly visits before or after routinely 
performed spirometry. We instructed participants to take a 
maximal inspiration and cough twice on each of 2 different 
agar plates, Sabouraud dextrose agar and Columbia blood 
agar, held at a 5-cm distance from the participant’s mouth. 
In addition, we collected a sputum sample on the same day 
or alternatively within a month if the participant was un-
able to produce sputum during the visit. We incubated Sa-
bouraud dextrose agar cough plates at 28°C and Columbia 
blood agar cough plates at 36°C for 3 weeks and inspected 
daily for bacterial and fungal growth. We processed spu-
tum samples according to CF guidelines (3). We collected 
individual CFUs (up to a maximum of 20 CFUs per sam-
ple) from cough plates and sputum cultures and genotyped 
A. fumigatus CFUs using microsatellite genotyping (5). We 
considered the detection of identical A. fumigatus geno-
types from cough plates and sputum samples as proof of 
aerosolization of A. fumigatus from humans. We genotyped 
up to 6 sputum cultures of stored A. fumigatus isolates from 
each participant.
This study was reviewed by the institutional review 
board, which considered the study exempt from further in-
stitutional review board oversight in accordance with the 
law in the Netherlands on research with humans. All par-
ticipants provided informed consent.
We cultured A. fumigatus from 18 (60%) sputum 
samples collected from 11 different participants (Table). 
A. fumigatus was also recovered from 3 (17%) of the 18 
corresponding cough plate samples; these 3 samples were 
from 2 different participants. In both cases, cough plates 
had been acquired after the participant had undergone 
spirometry. Genotyping of the A. fumigatus isolates from 
sputum samples and cough plates from both participants 
showed identical genotypes. One participant was colonized 
with at least 10 different A. fumigatus genotypes (Figure). 
In this participant, the genotype recovered from the cough 
plate was not found in the sputum sample collected at the 
same visit but in the sputum sample recovered at the next 
visit. The second participant was colonized with a single 
genotype, which was recovered from multiple cough plates 
and sputum samples.
We also assessed for bacterial species present on 
cough plates and in sputum samples to enable comparison 
of transmission frequencies among pathogens. The cough 
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secretion frequency for Pseudomonas aeruginosa was 67% 
(10/15) and for Staphylococcus aureus was 19% (3/16) 
(Table). No growth of Stenotrophomonas maltophilia on 
cough plates was observed.
Our study demonstrates that A. fumigatus can be re-
covered from cough aerosols from colonized CF patients 
with a similar frequency as S. aureus. This aerosolization is 
strikingly occurring in CF outpatients without any cavitary 
lesions or other serious complications. Cavitary lesions can 
facilitate sporulation of A. fumigatus inside patient lungs 
and thereby aids in fungal secretion.
By continuously monitoring indoor airborne fun-
gal contamination with electrostatic dustfall collectors, 
Lemaire et al. identified patient airways as the source of 
A. fumigatus contamination in an intensive care unit (4). 
Microsatellite genotyping showed that the airborne A. fu-
migatus and isolates from the patient’s respiratory samples 
were identical. That observation and our study results indi-
cate that the current consensus that transmission of A. fu-
migatus from colonized or infected patients does not occur 
should be reconsidered.
Although CF patients are typically colonized with 
unique A. fumigatus genotypes, several studies report the re-
covery of identical A. fumigatus genotypes from different CF 
patients (6). These genotypes could not be linked to a com-
mon environmental source and thus remained unexplained, 
but identical genotypes in different patients might point 
toward patient-to-patient transmission (6). Patient-derived 
 
Table. Characteristics of and growth of Aspergillus fumigatus, Pseudomonas aeruginosa, Staphylococcus aureus, and 
Stenotrophomonas maltophilia in sputum samples and on cough plates from 15 cystic fibrosis patients, the Netherlands, 2017–2018* 
Pt. 
no. 
Age, 
y/sex 
FEV1, L 
(% 
predicted) 
Peak 
flow, 
L/s 
AB/AF 
use 
Growth on first/second cough plates 
 
Cultured from first/second sputum sample 
A. 
fumigatus 
P. 
aeruginosa 
S. 
aureus 
S. 
maltophilia 
A. 
fumigatus 
P. 
aeruginosa 
S. 
aureus 
S. 
maltophilia 
1 23/F 2.7 (85) 7.9 Yes/no –/– +/– –/– –/–  –/– +/+ +/+ +/– 
2 20/F 4.0 (101) 8.6 Yes/no –/– –/– –/– –/+  –/ND –/ND +/ND +/ND 
3 22/F 2.3 (74) 7.9 Yes/no –/– –/– –/+ –/–  +/+ –/– +/+ –/– 
4 20/M 3.2 (61) 7.4 Yes/no +/– –/– –/– –/–  +/+ –/– +/+ –/– 
5 49/F 2.3 (74) 7.7 No/no –/– –/– –/– –/–  +/– –/– +/+ –/– 
6 43/F 2.7 (82) 7.2 Yes/no –/– –/– –/– –/–  +/+ +/+ –/– –/– 
7 26/M 4.6 (106) 10.9 Yes/no –/– –/– +/+ –/–  +/ND –/ND +/ND –/ND 
8 39/F 1.0 (33) 5.7 Yes/no –/– –/– –/+ –/–  +/+ –/– –/– +/+ 
9 49/M 1.2 (31) 3.4 Yes/no –/– +/+ –/– –/–  +/+ +/+ –/– –/– 
10 22/M 2.0 (41) 7.8 Yes/no –/– +/+ –/– –/–  +/– +/+ +/+ –/– 
11 58/F 2.2 (79) 5.1 Yes/no –/– –/– –/– –/–  –/– +/+ +/– –/– 
12 31/M 2.0 (41) 5.3 Yes/no –/– +/+ +/+ –/–  –/+ –/+ –/+ –/– 
13 51/F 0.7 (26) 3.5 Yes/no –/– +/+ –/– –/–  –/– +/+ +/+ –/– 
14 30/M 2.5 (50) 8.7 Yes/no –/– +/+ –/– –/–  +/+ +/+ –/– –/+ 
15 27/F 3.8 (102) 8.4 Yes/no +/+ –/– –/– –/–  +/+ –/– –/– –/– 
*AB, antibiotic; AF, antifungal; FEV1, forced expiratory volume in 1 second; ND, not done; Pt, patient; +, positive; –, negative. 
 
Figure. Genotyping results of 
Aspergillus fumigatus isolates 
in sputum cultures and on 
cough plates obtained from 
2 participants with cystic 
fibrosis demonstrating aerosol 
formation of A. fumigatus, the 
Netherlands, 2015–2018. For 
samples collected after August 
2017, a maximum of 20 isolates 
per sputum culture were saved. 
For samples collected earlier, 
only 1 sputum sample isolate 
was saved. Genotypes of the 
isolates collected from patient 
4 (A) and 15 (B) are indicated. 
The superscript number 
indicates the number of isolates 
of that same genotype cultured 
from the collected sample.
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azole resistance mutations have been reported in CF pa-
tient (7) and environmental (8) isolates. The mechanism 
for acquisition of azole resistance is unknown for envi-
ronmental isolates, but resistance might have developed in 
isolates during human infection or colonization and then 
subsequently spread into the environment. Our observation 
of A. fumigatus in cough aerosols suggests droplet or air-
borne transmission as potential routes of patient to patient 
transmission. Traits such as azole resistance might spread 
through cough aerosols from patient to patient or from pa-
tient to environment. Both participants with positive cough 
plates had undergone spirometry before coughing, indicat-
ing that maximal inspiration and expiration might facilitate 
the release of A. fumigatus.
Aerosolized A. fumigatus conidia from environmen-
tal sources could represent a greater and more continuous 
burden for CF patients than potentially aerosolized conidia 
from patients. However, some studies suggest that A. fu-
migatus in chronically infected patients undergoes an evo-
lutionary trajectory resulting in strains with specific traits 
that are better adapted to the lung environment (9,10). En-
dogenous and exogenous stress factors, such as host im-
munity or exposure to antifungal azoles, might result in the 
selection of traits that are better able to resist these stress 
factors (11). Isolates that are better adapted to the lung en-
vironment might have a greater propensity than environ-
mental isolates to successfully colonize and persist in the 
airways of CF patients. In CF, 42% of azole resistance is 
derived through in-host selection and is thought to be as-
sociated with prolonged (prophylactic) use of anti-Asper-
gillus azoles (12,13). Passaging through the lungs of CF 
patients conceivably could provide A. fumigatus isolates 
the opportunity to acquire specific traits that increase their 
ability to survive in different environments. Evolution ex-
periments have confirmed the potential of A. fumigatus to 
rapidly adapt to various environments (9).
Conclusions
In summary, our results show that A. fumigatus can be 
recovered from cough aerosols of colonized CF patients. 
These findings underscore the need for additional stud-
ies to further elaborate transmission dynamics of A. fu-
migatus, evaluate if patient-to-patient transmission oc-
curs, and determine if additional infection prevention 
measures are required.
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